Old North State Trust LLC Has $589,000 Stake in Pfizer Inc. (NYSE:PFE)

Old North State Trust LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,194 shares of the biopharmaceutical company’s stock after selling 2,234 shares during the quarter. Old North State Trust LLC’s holdings in Pfizer were worth $589,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the last quarter. Lipe & Dalton boosted its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. grew its stake in Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 401 shares in the last quarter. Finally, Providence Capital Advisors LLC increased its position in Pfizer by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after purchasing an additional 409 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.61 on Wednesday. The firm has a market capitalization of $134.23 billion, a PE ratio of 16.74, a PEG ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business’s 50 day moving average is $23.28 and its 200-day moving average is $25.12.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 earnings per share. The business’s revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.29%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.